

ORIGINAL RESEARCH

SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes



Ammar W. Bhatti, DO,^a Rushin Patel, MD,^a Sourbha S. Dani, MD,^a Sumanth Khadke, MD,^a Bhargav Makwana, MD,^a Candace Lessey, MD,^a Jui Shah, MD,^a Zaid Al-Husami, MD,^a Eric H. Yang, MD,^b Paaladinesh Thavendiranathan, MD, SM,^c Tomas G. Neilan, MD,^d Diego Sadler, MD,^e Richard K. Cheng, MD, MSc,^f Susan F. Dent, MD,^g Jennifer Liu, MD,^h Teresa Lopez-Fernandez, MD,^{i,j} Joerg Herrmann, MD,^k Marielle Scherrer-Crosbie, MD, PhD,^l Daniel J. Lenihan, MD,^m Salim S. Hayek, MD,ⁿ Bonnie Ky, MD, MSCE,^o Anita Deswal, MD, MPH,^p Ana Barac, MD, PhD,^q Anju Nohria, MD,^r Sarju Ganatra, MD^a

ABSTRACT

BACKGROUND Specific cancer treatments can lead to cancer therapy-related cardiac dysfunction (CTRCD). Sodium glucose cotransporter-2 inhibitors (SGLT2is) can potentially prevent these cardiotoxic effects.

OBJECTIVES This study sought to determine whether SGLT2i use is associated with a lower incidence of CTRCD in patients with type 2 diabetes mellitus (T2DM) and cancer, exposed to potentially cardiotoxic antineoplastic agents, and without a prior documented history of cardiomyopathy or heart failure.

METHODS We conducted a retrospective analysis of patients aged ≥ 18 years within the TriNetX database with T2DM, cancer, exposure to cardiotoxic therapies, and no prior documented history of cardiomyopathy or heart failure. Patients were categorized by SGLT2i use. After propensity score matching, outcomes were compared over 12 months using Cox proportional HRs. Subgroup analyses focusing on different cancer therapy classes were performed.

RESULTS The study included 8,675 propensity-matched patients in each cohort (mean age = ~ 65 years, 42% females, 71% White, $\sim 19\%$ gastrointestinal malignancy, and $\sim 25\%$ anthracyclines). Patients prescribed SGLT2is had a lower risk of developing CTRCD (HR: 0.76; 95% CI: 0.69–0.84). SGLT2is also reduced heart failure exacerbations (HR: 0.81; 95% CI: 0.72–0.90), all-cause mortality (HR: 0.67; 95% CI: 0.61–0.74), and all-cause hospitalizations/emergency department visits (HR: 0.93; 95% CI: 0.89–0.97). Subgroup analyses also demonstrated reduced CTRCD risk across various classes of cancer therapies in patients prescribed SGLT2is.

CONCLUSIONS SGLT2i administration was associated with a significantly decreased risk of developing CTRCD in patients with T2DM and cancer. (JACC CardioOncol. 2024;6:863–875) © 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

From the ^aCardio-Oncology Program, Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts, USA; ^bUniversity of California-Los Angeles, Cardio-Oncology Program, Division of Cardiology, Department of Medicine, University of California-Los Angeles, Los Angeles, California, USA; ^cDepartment of Medicine, Division of Cardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada; ^dCardio-Oncology Program, Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA; ^eCardio-Oncology Section, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Weston, Florida, USA; ^fDivision of Cardiology, University of Washington, Seattle, Washington, USA; ^gDuke Cancer Institute, Department of Medicine, Duke University, Durham, North

ABBREVIATIONS AND ACRONYMS

CTRCD = cancer therapy-related cardiac dysfunction

ED = emergency department

EHR = electronic health record

GDMT = guideline-directed medical therapy

HF = heart failure

ICD-10 = International Classification of Diseases-10th Revision

PSM = propensity score matching

SGLT2 = sodium glucose co-transporter 2

SGLT2i = sodium glucose co-transporter 2 inhibitor

T2DM = type 2 diabetes mellitus

TKI = tyrosine kinase inhibitor

Sodium glucose co-transporter 2 inhibitors (SGLT2is), initially developed for type 2 diabetes mellitus (T2DM), have proven effective in reducing heart failure (HF) hospitalization and cardiovascular death independent of T2DM status or degree of left ventricular dysfunction.^{1,2} These benefits extend beyond glucose lowering, encompassing cardiac metabolism improvements, cardiac preload reduction, and attenuation of oxidative stress and inflammation.^{3,4}

Asymptomatic cardiac dysfunction or symptomatic HF can develop secondary to various antineoplastic therapies, a constellation referred to as cancer therapy-related dysfunction (CTRCD).⁵⁻¹¹ The clinical implications of this entity can be substantial, including premature termination of cancer therapy and disease-related morbidity and mortality.¹¹⁻¹⁴ Interest has henceforth mounted to effectively target cancer cells

while minimizing adverse effects on the cardiovascular system.¹² In keeping with this interest, “cardioprotective” effects have been reported for SGLT2is in patients with anthracycline-associated CTRCD,¹⁵ including a reduction in HF hospitalizations and cardiac events.^{4,16} Furthermore, there is evidence that SGLT2is may offer more significant benefits than other conventional 3-agent guideline-directed medical therapy (GDMT) in patients with CTRCD, leading to a lower rate of acute HF exacerbations and all-cause mortality.¹⁷⁻²⁰

CTRCD can arise from various mechanisms depending on the specific agents involved. Anthracyclines, which have been shown to have a ~10% incidence of CTRCD,²¹ predominantly induce cardiac damage by instigating the production of reactive oxygen species, disrupting mitochondrial function, and

causing direct cardiomyocyte injury.¹⁵ Conversely, targeted therapies interfere with signaling pathways necessary for cardioprotection, resulting in dysfunction.²⁰ Additionally, these therapies can induce electrolyte imbalances, predisposing individuals to arrhythmias.¹⁶

Given the established cardiovascular benefits of SGLT2is in HF and the shared pathways of cardiovascular dysfunction in T2DM and CTRCD, exploring the potential of SGLT2i use as a primary prevention strategy against CTRCD induced by cardiotoxic cancer therapies is important.^{20,22} Leveraging an extensive electronic health record (EHR) database, this retrospective study aimed to examine the association of SGLT2i as a preventive measure against CTRCD in patients with T2DM undergoing potentially cardiotoxic cancer therapies, expanding our understanding of their association in cardioprotection beyond T2DM and HF. This study also aimed to examine a number of secondary outcomes including HF exacerbations, all-cause mortality, all-cause hospitalization or emergency department (ED) visit, new onset atrial fibrillation/flutter, new onset metastatic cancer, and need for further systemic anticancer therapy.

METHODOLOGY

DATA SOURCE. We conducted a retrospective observational cohort study using the TriNetX research network database from January 1, 2013, to October 31, 2022. The TriNetX network offers access to EHRs of approximately 110 million patients from diverse U.S. health care institutions. This network provides aggregate, deidentified data per the deidentification standards defined in section §164.514(a) of the Health Insurance Portability and Accountability Act Privacy Rule. Because this study used deidentified aggregate data, it was determined to be

Carolina; ^bCardio-Oncology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA; ⁱDivision of Cardiology, Cardio-Oncology Unit, La Paz University Hospital, Hospital La Paz Institute for Health Research, Madrid, Spain; ^jDivision of Cardiology, Quirónsalud Madrid University Hospital, Madrid, Spain; ^kDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA; ^lDivision of Cardiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA; ^mCardiovascular Division, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA; ⁿDivision of Cardiology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA; ^oThalheimer Center for Cardio-Oncology, Abramson Cancer Center and Division of Cardiovascular Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; ^pDepartment of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA; ^qInova Schar Heart and Vascular Institute, Inova Schar Cancer Institute, Fairfax, Virginia, USA; and the ^rDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

This paper was handled by Saro Armenian, DO, MPH, Deputy Editor. Dr Ky recused herself because of a conflict of interest. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

Manuscript received June 7, 2024; accepted August 3, 2024.

exempt by the Institutional Review Board of Lahey Hospital and Medical Center.

PATIENT POPULATION. We identified adult patients (≥ 18 years old) with T2DM and cancer, exposed to potentially cardiotoxic antineoplastic medications, and without a prior documented history of cardiomyopathy or HF using International Classification of Diseases-10th Revision (ICD-10) codes. Patients were further categorized into 2 cohorts based on baseline (preantineoplastic therapy) exposure to SGLT2i (empagliflozin, dapagliflozin, or canagliflozin) use using RxNorm codes and EHR curated data. The study cohort included patients exposed to a variety of potentially cardiotoxic antineoplastic agents such as anthracyclines, alkylating agents, antimetabolites, monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and proteasome inhibitors.¹⁸ Various antineoplastic therapies with potential cardiotoxicity in our study were included based on the 2020 European Society of Medical Oncology consensus recommendations.²³ The [Supplemental Appendix](#) describes the Current Procedural Terminology and ICD-10 codes used for cohort identification and study window definitions. Additionally, subgroup analyses were conducted to assess the impact of baseline SGLT2i use on incident CTRCD based on the class of antineoplastic therapy received. Data analysis was performed on October 31, 2023. This study was reported per the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.

STUDY ENDPOINTS. The index date was the initiation of potentially cardiotoxic antineoplastic therapy. All outcomes were based on a 12-month follow-up period. A 12-month follow-up period was chosen to exclude patients outside of this window given that cardiomyopathy outside of 12 months may not be caused by exposure to cancer therapy.^{21,24} The primary outcome of interest was incident CTRCD, defined using ICD-10 codes for new onset cardiomyopathy or HF or requiring intravenous loop diuretic agents at any time within 12 months from the index event after excluding ischemic heart disease as an etiology. To further validate CTRCD diagnosis, we analyzed rates of GDMT use, including angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor neprilysin inhibitors, beta-blockers, or mineralocorticoid receptor antagonists. Notably, 93.6% of patients with CTRCD received at least 1 of these GDMT medications. Secondary endpoints included the following additional outcomes: HF exacerbations, all-cause mortality, all-cause hospitalization or ED visit, new onset atrial fibrillation/flutter, new onset metastatic cancer, and

the need for further systemic antineoplastic therapy. The [Supplemental Appendix](#) elaborates on outcome definitions, with CTRCD further analyzed in the subgroup analyses mentioned previously (class of antineoplastic therapy).

STATISTICAL ANALYSIS. Continuous variables are presented as mean \pm SD, whereas categorical variables are presented as number (%) as appropriate. Baseline characteristics were compared between SGLT2i users and nonusers using independent samples Student's *t*-tests for continuous variables and chi-square tests for categorical variables. To mitigate baseline differences between cohorts, 1:1 propensity score matching was conducted using greedy nearest neighbor matching with a caliper of 0.1 times the pooled SD of the linear propensity scores. The standardized mean difference represents the difference between the means of 2 groups in terms of SD units, assessing balance in measured variables in the sample weighted by the inverse probability of treatment. The variables were selected based on their potential impact on overall and cardiovascular outcomes.

Post-PSM, adjusted outcomes were compared between cohorts using HRs. Survival analysis was conducted using Kaplan-Meier curves and Cox proportional hazards models, with statistical significance set at *P* value < 0.05 . Statistical analyses were executed using integrated R (The R Foundation) for statistical computing on the TriNetX platform.

Sensitivity analysis included calculating the E value to assess robustness against bias from unmeasured confounding or omitted covariates for primary and secondary outcomes. A high E value indicates a stronger unmeasured confounder would be required to nullify the observed association between the exposure and the outcome. Furthermore, falsification outcomes such as pneumonia and gastrointestinal bleeding were assessed.

RESULTS

STUDY POPULATION. We identified a total of 95,203 patients with T2DM and cancer, exposed to potentially cardiotoxic antineoplastic agents, and without a prior documented history of cardiomyopathy or HF. Among these, 9,403 patients were on SGLT2is, and 85,800 patients were not on SGLT2is. After PSM, 8,675 patients in each cohort were included in this analysis.

PATIENT CHARACTERISTICS. The baseline characteristics of the study patients, before and after PSM, are shown in [Table 1](#). In the unmatched cohort, patients on SGLT2is were less likely to be female (41.6% vs 46.0%; *P* < 0.001) and Hispanic (7.5% vs

TABLE 1 Baseline Characteristics of the Study Cohort Before and After Propensity Score Matching Based on SGLT2i Treatment

	Before Propensity Matching			After Propensity Matching		
	SGLT2i Cohort (n = 9,403)	No SGLT2i Cohort (n = 85,800)	SMD	SGLT2i Cohort (n = 8,675)	No SGLT2i Cohort (n = 8,675)	SMD
Demographics						
Mean age, y	65.5 ± 10.5	65.0 ± 12.5	0.039	65.5 ± 10.5	65.7 ± 11.6	0.018
Female	3,910 (41.6)	39,429 (46.0)	0.088	3,602 (41.5)	3,648 (42.1)	0.011
White	6,638 (70.6)	60,006 (69.9)	0.014	6,133 (70.7)	6,197 (71.4)	0.016
Black or African American	1,089 (11.6)	9,850 (11.5)	0.003	983 (11.3)	966 (11.1)	0.006
Hispanic or Latino	708 (7.5)	7,307 (8.5)	0.036	665 (7.7)	619 (7.1)	0.020
Non-Hispanic/Latino	6,713 (71.4)	61,840 (72.1)	0.015	6,160 (71.0)	6,109 (70.4)	0.013
Comorbidities						
Hypertension	6,938 (73.8)	49,189 (57.3)	0.352	6,320 (72.9)	6,251 (72.1)	0.018
Hyperlipidemia	6,111 (65.0)	37,042 (43.2)	0.449	5,530 (63.7)	5,535 (63.8)	0.001
Overweight and obesity	2,638 (28.1)	14,646 (17.1)	0.265	2,356 (27.2)	2,026 (23.4)	0.088
Ischemic heart disease	2,226 (23.7)	12,864 (15.0)	0.221	1,979 (22.8)	1,990 (22.9)	0.003
Atrial fibrillation/flutter	888 (9.4)	5,473 (6.4)	0.114	774 (8.9)	771 (8.9)	0.001
Medications						
Beta-blockers	3,749 (39.9)	25,098 (29.3)	0.225	3,382 (39.0)	3,388 (39.1)	0.001
ACE inhibitors	2,733 (29.1)	16,693 (19.5)	0.226	2,492 (28.7)	2,522 (29.1)	0.008
Angiotensin receptor blocker	2,429 (25.8)	11,004 (12.8)	0.334	2,089 (24.1)	2,149 (24.8)	0.016
Sacubitril/valsartan	148 (1.6)	46 (0.1)	0.170	49 (0.6)	43 (0.5)	0.010
Statin	5,714 (60.8)	29,860 (34.8)	0.538	5,141 (59.3)	5,136 (59.2)	0.001
Insulin	4,417 (47.0)	25,105 (29.3)	0.371	3,989 (46.0)	4,039 (46.6)	0.012
Exenatide	159 (1.7)	215 (0.3)	0.147	127 (1.5)	128 (1.5)	0.001
Metformin	4,616 (49.1)	18,164 (21.2)	0.612	4,108 (47.4)	4,165 (48.0)	0.013
Glipizide	1,227 (13.0)	4,317 (5.0)	0.282	1,094 (12.6)	1,159 (13.4)	0.022
Type of malignancy						
Breast	2,472 (26.3)	22,136 (25.8)	0.017	2,273 (26.2)	2,220 (25.6)	0.061
Lymphomas	1,956 (20.8)	17,332 (20.2)	0.097	1,813 (20.9)	1,683 (19.4)	0.045
Multiple myeloma and myelodysplastic syndromes	1,202 (12.8)	10,639 (12.4)	0.018	1,084 (12.5)	1,224 (14.1)	0.048
Genitourinary	446 (4.7)	4,612 (5.4)	0.052	390 (4.5)	399 (4.6)	0.006
Gastrointestinal	1,775 (18.9)	15,701 (18.3)	0.03	1,683 (19.4)	1,691 (19.5)	0.002
Gynecologic	649 (6.9)	7,036 (8.2)	0.083	599 (6.9)	642 (7.4)	0.034
Respiratory and intrathoracic organs	348 (3.7)	3,775 (4.4)	0.056	312 (3.6)	304 (3.5)	0.004
Mesothelial and soft tissue	555 (5.9)	4,569 (5.3)	0.046	521 (6.0)	512 (5.9)	0.008
Metastatic malignancy	1,539 (16.4)	20,793 (24.2)	0.197	1,440 (16.6)	1,349 (15.6)	0.029
Laboratory tests						
HbA1c ≥7%	5,315 (56.5)	16,456 (19.2)	0.834	4,702 (54.2)	4,814 (55.5)	0.026
Creatinine, mg/dL	1.0 ± 0.5	1.1 ± 1.3	0.058	1.0 ± 0.5	1.2 ± 1.2	0.019
LDL cholesterol ≥130, mg/dL	660 (7.0)	4,262 (5.0)	0.087	598 (6.9)	634 (7.3)	0.016
CRP ≥5, mg/L	668 (7.1)	5,738 (6.7)	0.016	606 (7.0)	567 (6.5)	0.018
Health care use						
Outpatient visits	7,760 (82.5)	62,633 (73.0)	0.231	7,102 (81.9)	7,011 (80.8)	0.027
Hospitalizations	1,672 (17.8)	17,314 (20.2)	0.061	1,520 (17.5)	1,495 (17.2)	0.008
ED visits	2,510 (26.7)	20,106 (23.4)	0.075	2,264 (26.1)	2,233 (25.7)	0.008

Values are mean ± SD or n (%).

ACE = angiotensin-converting enzyme; CRP = C-reactive protein; ED = emergency department; HbA1C = glycosylated hemoglobin; LDL = low-density lipoprotein; SGLT2i = sodium glucose co-transporter 2 inhibitor; SMD = standardized mean difference.

8.5%; $P = 0.001$) compared to patients who were not on SGLT2is (Table 1). Additionally, before PSM, patients treated with SGLT2is had a higher prevalence of hypertension, ischemic heart disease, overweight/obesity, chronic kidney disease, and atrial fibrillation/flutter. After PSM, the 2 cohorts

were well matched for demographics, comorbidities, medication use at baseline, and various laboratory values.

Concerning patients' oncologic characteristics, breast malignancies were most common followed by lymphomas and gastrointestinal malignancies

Antineoplastic Therapy (After Propensity Matching)			
	SGLT2i Cohort (N = 8,675)	No SGLT2i Cohort (N = 8,675)	SMD
Anthracyclines	2,126 (24.5)	2,135 (24.6)	0.003
Antimetabolites	1,648 (19)	1,690 (19.5)	0.010
Monoclonal antibodies	1,834 (21.1)	1,763 (20.3)	0.040
Small-molecule TKIs	1,465 (16.9)	1,490 (17.2)	0.020
Proteasome Inhibitors	720 (8.3)	722 (8.3)	<0.001
Alkylating agents	622 (7.2)	620 (7.1)	0.001
Aromatase inhibitor	260 (3.0)	255 (2.9)	0.020

Values are n (%).

TKI = tyrosine kinase inhibitor; other abbreviations as in [Table 1](#).

PRIMARY OUTCOMES. After matching, within a 12-month follow-up period, there was a total of 646 patients (7.45%) on SGLT2is that developed CTRCD compared to 948 patients (10.9%) who were not on SGLT2is (HR: 0.76; 95% CI: 0.69-0.84; $P < 0.001$) (Table 3). In the subgroup analysis on different classes of antineoplastic therapies (Figure 1), SGLT2i use was associated with a significantly lower risk of developing CTRCD in patients exposed to anthracyclines (HR: 0.70; 95% CI: 0.58-0.85; $P < 0.001$), monoclonal antibodies (HR: 0.81; 95% CI: 0.66-0.98; $P = 0.03$), antimetabolites (HR: 0.75; 95% CI: 0.65-0.86; $P < 0.001$), small-molecule TKIs (HR: 0.67; 95% CI: 0.54-0.83; $P < 0.001$), and alkylating agents (HR: 0.63; 95% CI: 0.53-0.76; $P < 0.001$). In subgroup analysis focused on individual SGLT2i therapies, empagliflozin was associated with a significantly lower risk of developing CTRCD (HR: 0.78; 95% CI: 0.70-0.87; $P < 0.001$) compared with


SECONDARY OUTCOMES. The secondary outcomes of HF exacerbations (**Figure 2**) (HR: 0.81; 95% CI: 0.72-0.90; $P < 0.001$), all-cause mortality (HR: 0.67; 95% CI: 0.61-0.74; $P < 0.001$), hospitalization or ED visit (HR: 0.93; 95% CI: 0.89-0.97; $P < 0.001$), new onset atrial fibrillation/flutter (HR: 0.74; 95% CI: 0.62-0.89; $P = 0.001$), new onset metastatic cancer (HR: 0.66; 95% CI: 0.58-0.75; $P < 0.001$), and systemic antineoplastic therapy (HR: 0.67; 95% CI: 0.64-0.69; $P < 0.001$) were significantly lower in patients on SGLT2is compared to patients who were not on SGLT2is (**Table 3**). Falsification analysis of gastrointestinal bleeding and pneumonia outcomes led to insignificant event rates as shown in **Table 4**.

In this retrospective cohort analysis of patients with T2DM and cancer, exposure to potentially cardiotoxic antineoplastic therapies, and no prior documented history of cardiomyopathy or HF, the use of SGLT2is at baseline was associated with a significantly reduced risk of CTRCD during a 12-month follow-up period (**Figure 3, Central Illustration**). We previously demonstrated the benefits of SGLT2is in patients with T2DM and prevalent CTRCD who were on contemporary GDMT.¹⁹ This study adds to the literature by demonstrating the efficacy of SGLT2is as a preventative strategy to reduce the risk of CTRCD in patients with cancer and T2DM receiving potentially cardiotoxic antineoplastic therapies. In addition, we also demonstrated that the prescription of SGLT2is in this population was associated with a significantly decreased risk of HF exacerbations, all-cause mortality, all-cause hospitalizations/ED visits, new onset

	SGLT2i Cohort (N = 8,675) ^a	No SGLT2i Cohort (N = 8,675)	HR (95% CI)	P Value	E Value for HR	E Value for Lower CI of HR
Primary outcome						
CTRCD	646 (7.45)	948 (10.9)	0.76 (0.69-0.84)	<0.001	1.96	2.26
Secondary outcomes						
HF exacerbation	576 (6.6)	744 (8.6)	0.81 (0.72-0.90)	<0.001	1.81	2.11
All-cause mortality	657 (7.6)	1,033 (11.9)	0.67 (0.61-0.74)	<0.001	2.34	2.66
Hospitalization or ED visit	3,537 (40.8)	3,893 (44.9)	0.93 (0.89-0.97)	<0.001	1.39	1.51
New onset Afib/flutter	203 (2.34)	290 (3.34)	0.74 (0.62-0.89)	0.001	2.08	2.62
New onset metastatic cancer	394 (4.54)	656 (7.56)	0.66 (0.58-0.75)	<0.001	2.45	2.84
Systemic antineoplastic therapy	3,991 (46.0)	5,336 (61.5)	0.67 (0.64-0.69)	<0.001	2.40	2.51


Afib = atrial fibrillation; CTRCD = cancer therapy-related cardiac dysfunction; HF = heart failure; other abbreviations as in [Table 1](#).

FIGURE 1 Forest Plot for Subgroup Analysis



Forest plot showing HRs and their corresponding 95% CIs for a subgroup analysis of the class of antineoplastic therapy and the risk of developing cancer therapy-related cardiac dysfunction while on sodium glucose co-transporter 2 inhibitor (SGLT2i). Ab = antibody; SGLT2 = sodium glucose co-transporter 2; TKI = tyrosine kinase inhibitor.

FIGURE 2 Kaplan-Meier Curve for Heart Failure Exacerbation



A graph depicting the Kaplan-Meier curve for heart failure exacerbations for patients on sodium glucose co-transporter 2 inhibitor (SGLT2i) vs no SGLT2i.

TABLE 4 Falsification Outcomes			
	SGLT2i Cohort (n = 8,675)	No SGLT2i Cohort (n = 8,675)	P Value
Gastrointestinal bleeding	59 (0.68)	101 (1.16)	0.47
Pneumonia	545 (6.28)	705 (8.13)	0.56

Values are n (%).
SGLT2i = sodium glucose co-transporter 2 inhibitor.


atrial fibrillation/flutter, new onset metastatic cancer, and the need for systemic neoplastic therapy. Furthermore, we also performed a subgroup analysis based on various classes of antineoplastic treatments and found a consistent beneficial association between baseline use of SGLT2is and decreased risk of CTRCD.

Although the role of several agents commonly used in the treatment of HF, such as angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and mineralocorticoid receptor antagonists, has been examined for primary prevention of CTRCD,²⁵⁻³¹ the data remain conflicting with marginal benefits at best.^{32,33} More recently, the STOP-CA (Atorvastatin for Anthracycline-Associated Cardiac Dysfunction) trial demonstrated that

initiating statins before starting higher doses of anthracycline-based therapy reduced the incidence of CTRCD.³⁴




Our study builds on the findings of a previous smaller study, which showed the potential role of SGLT2is in the primary prevention of CTRCD in patients with cancer and T2DM.¹⁸ However, the study was limited to patients receiving anthracycline only, with <100 patients in the SGLT2i cohort, and the assessed outcome was HF hospitalization only rather than any CTRCD. To our knowledge, our study is the largest study, albeit observational, to demonstrate the use of SGLT2is at baseline among patients with a history of T2DM and cancer who are exposed to potentially cardiotoxic antineoplastic therapies is associated with a lower incidence of CTRCD and associated adverse cardiovascular outcomes and health care use. Ours is also the first to demonstrate this in antineoplastic therapies, including but not limited to anthracycline-based therapies.

The mechanisms through which SGLT2is may offer cardioprotection in patients with T2DM in the context of cardiotoxic cancer therapies are still not fully understood. Although limited access to granular-level data precluded stratification of the analysis by



CENTRAL ILLUSTRATION Sodium Glucose Co-Transporter 2 Inhibitors in the Prevention of Cancer Therapy-Related Cardiac Dysfunction

Adult Patients With Type II Diabetes and Cancer Exposed to Potentially Cardiotoxic Antineoplastic Medications



cancer subtype, the cardioprotective mechanisms of SGLT2i in CTRCD and its potential for cancer progression inhibition exhibit remarkable concordance.^{3,4} These mechanisms involve modulation of cellular metabolism, attenuation of oxidative stress, and dampening of inflammatory responses.^{3,4} Dabour et al²⁰ reviewed evidence from preclinical and clinical studies suggesting that SGLT2is can mitigate systemic inflammation and oxidative stress, which are well-established contributors to both cardiovascular dysfunction and cancer progression. The anticancer effects of SGLT2is were associated with up-regulation of adenosine monophosphate-activated protein kinase and down-regulation of glucose uptake, mitochondrial complex I, phosphoinositide 3-kinase/AKT³⁵ signaling, and the Hippo pathway.²⁰ Conversely, the cardioprotective effects were attributed to enhanced energy metabolism, mitochondrial biogenesis, autophagy, and ketone body use alongside a reduction in endoplasmic reticulum stress and ferroptosis, ultimately leading to diminished oxidative stress and inflammation.²⁰ Additionally, Packer et al³⁶ demonstrated that SGLT2is can modulate key signaling pathways like adenosine monophosphate-activated protein kinase and mammalian target of rapamycin, which are implicated in both cardiovascular and cancer biology. Translational research in mice following intraperitoneal doxorubicin injection has provided valuable insights.³⁷ Using cardiac magnetic resonance, this study found that mice treated with empagliflozin exhibited reduced hypertrophy, reduced ventricular remodeling, and enhanced fractional shortening compared to untreated mice. Interestingly, the study also revealed that sodium glucose co-transporter 1 expression was more prevalent than sodium glucose co-transporter 2 (SGLT2) in mouse cardiac myocytes, particularly in the left ventricle. Treatment with SGLT2is led to elevated beta-hydroxybutyrate levels, which protected mice against doxorubicin-induced suppression of anti-oxidative gene expression, thus mitigating oxidative stress. Additionally, dapagliflozin treatment has been demonstrated to reduce intracellular calcium and proinflammatory cytokine expression in HL-1 adult cardiomyocytes exposed to doxorubicin and trastuzumab.³⁸ These findings collectively suggest that

SGLT2is may confer cardioprotection in the setting of cardiotoxic cancer therapies by reducing hypertrophy, improving cardiac function, and mitigating oxidative stress and inflammation. In our study, this could explain the decreased risk of HF exacerbations and all-cause hospitalizations/ED visits in patients treated with SGLT2is.


We also found a lower rate of all-cause mortality in the SGLT2i group aligning with the results of prior studies.¹⁷ This finding can be partly because of the reduced number of cardiac events and the promotion of a fasting-like state mitigating hyperinsulinemia, which closely mimic antineoplastic effects and slow tumor growth in breast and colon cancers along with gastrointestinal cancers, lung cancer, and liver tumors in mouse models.¹⁷

Our study also revealed a significant decrease in the incidence of new onset atrial arrhythmias with SGLT2i use, which could potentially avert the development of cardiomyopathy secondary to cancer-mediated atrial arrhythmias.³⁹⁻⁴² Several other studies have demonstrated the beneficial effects of SGLT2is on atrial arrhythmias in patients with T2DM, HF, or chronic kidney disease.^{43,44} These effects are believed to be mediated via increased natriuresis and anti-inflammatory and metabolic pathways.⁴⁵

Although CTRCD has been primarily discussed with anthracycline therapies, it is also associated with proteasome inhibitors, small-molecule TKIs, alkylating agents, human epidermal growth factor receptor 2 inhibitors, and antimetabolites.^{46,47} Our subgroup analysis highlighted the association of SGLT2is with a reduced risk of CTRCD across different classes of antineoplastic therapy in patients with T2DM and cancer. Specifically, we observed a significant reduction in the risk of CTRCD with anthracyclines, monoclonal antibodies, antimetabolites, small-molecule TKIs, and alkylating agents. Although lower risk with proteasome inhibitors was found, this was not statistically significant, possibly because of the small sample size, as shown in [Figure 1](#). Individual agents within different classes of antineoplastic therapies such as TKIs, antimetabolites, and monoclonal antibodies may have varying propensities of inducing cardiac dysfunction, whether it be directly or indirectly via mechanisms such as inducing

CENTRAL ILLUSTRATION Continued

This figure presents the results of a propensity score-matched analysis involving adults with cancer and type 2 diabetes mellitus who did not have a previous history of cardiomyopathy or heart failure. It examines their exposure to potentially cardiotoxic antineoplastic therapies and the incidence of cancer therapy-related cardiac dysfunction (CTRCD) based on whether or not patients were taking sodium glucose co-transporter 2 inhibitor (SGLT2i). Ab = antibody; SGLT2 = sodium glucose co-transporter 2; TKI = tyrosine kinase inhibitor.



arrhythmias.²³ However, small sample size restrictions limited our ability to perform cancer-based and individual cancer therapy-based stratified analysis. Furthermore, although mechanisms through which various antineoplastic therapy agents exert cardiotoxicity differ, there are potential commonalities through shared cellular-level metabolic pathways including but not limited to oxidative stress and inflammatory response.^{3,4,20} Given the ability of SGLT2is to modulate this pathway favorably, it is plausible that they may provide cardioprotective effects against a broad range of antineoplastic agents. This could begin to explain why our study showed that the effect on anthracyclines had a similar magnitude of risk as other agents such as antimetabolites and TKIs. Future studies capable of obtaining details such as antineoplastic dosing, timing, and combinations could help further clarify this.

Interestingly, in addition to cardiovascular benefits, our study found a significant decrease in all-cause mortality (Figure 4), the risk of new onset metastatic cancer, and the need for systemic antineoplastic therapy in the SGLT2i cohort. Although these measures are not equivalent to progression-free survival or overall survival, they can be used as

surrogates for such.^{48,49} Various studies suggest that SGLT2is may inhibit cancer cell proliferation by impeding glucose uptake. For instance, Komatsu et al⁵⁰ demonstrated that human breast cancer MCF-7 cells express SGLT2 receptors, and treatment with ipragliflozin significantly suppressed cell growth through membrane hyperpolarization and mitochondrial membrane instability. Functional SGLT2 receptors have also been identified in human pancreatic, prostate, and lung cancer cells, indicating their potential as early diagnostic and therapeutic targets.^{51,52} Villani et al⁵³ showed that canagliflozin inhibits cellular proliferation in mouse lung and prostate cancer cell models. Additionally, Lawler et al⁵⁴ observed an increased risk of colorectal cancer in diabetic patients, suggesting a potential role for SGLT2is in reducing this risk through effective diabetic control.

Additionally, our subgroup analysis on individual SGLT2i therapies showed that empagliflozin was associated with a significantly lower risk of developing CTRCD compared to dapagliflozin and canagliflozin. Empagliflozin improves cardiac energy metabolism, anti-inflammatory and antioxidative effects, and antifibrotic effects,²⁰ although direct

comparisons of individual SGLT2i propensity for these cardioprotective mechanisms in patients with CTRCD remains unknown. There have been other retrospective studies that have shown that in patients with HF, empagliflozin was associated with improved outcomes compared to dapagliflozin and or canagliflozin.^{55,56} Although the findings of our subgroup analysis are similar to other real-world data studies,^{55,56} there are both preclinical and prospective studies demonstrating that all SGLT2is can be effective, and the reason as to why our data showed only significance with empagliflozin may be because of the small sample size.²⁰ However, when interpreting these results, it should be noted that granular-level details such as dose and frequency were not obtainable. Although our findings are hypothesis generating and congruent with other retrospective studies, prospective studies are needed; as a result, our findings should be interpreted with caution.

STUDY LIMITATIONS. This study has several limitations. First, we used data from the TriNetX EHR database, which relies on International Classification of Diseases codes. This method is susceptible to coding errors and inherent biases within real-world databases. Additionally, the database limitations prevented the extraction of detailed medication information, including dosage, duration, route of administration, and specific combinations of cardiotoxic therapies. Although these factors likely impacted both cohorts equally, our analysis could not quantify their influence.

Second, our study population exclusively comprised patients with T2DM. Therefore, we cannot generalize these findings to assess SGLT2i as a primary preventative strategy for CTRCD in patients with cancer but without pre-existing T2DM receiving cardiotoxic therapies. Third, although the chosen 12-month follow-up period aligns with the most common timeframe for cardiotoxicity manifestation,²¹ the long-term effects of SGLT2is on CTRCD prevention beyond this period remain unknown. Fourth, the lack of individual-level data including specific event times and types prohibited us from performing competing risk analysis. Aggregate data sources provided summary statistics rather than patient-level information, making it challenging to accurately model competing risks. In addition, calculating cumulative incidence functions and cause-specific hazards was not possible because of the lack of time-to-event information. Aggregate data may not have allowed for detailed subgroup analysis identifying different effects across various patient populations.

Finally, despite PSM to reduce confounding bias, the possibility of residual confounding caused by unmeasured factors persists. To assess the robustness of our findings, we conducted sensitivity analyses and calculated E values. High E values suggest minimal influence of unmeasured confounding on observed effects. However, unmeasured socioeconomic factors, known to influence cardiovascular disease prevalence,⁵⁷ could still bias the results. These factors might limit access to SGLT2is in socioeconomically disadvantaged populations. We partially addressed this limitation by incorporating a prior health care use analysis into the matching process (details in [Table 1](#)). Additionally, we evaluated falsification outcomes (gastrointestinal bleeding and pneumonia) and observed similar rates between the cohorts, further supporting the validity of our approach.

CONCLUSIONS

In summary, our retrospective cohort analysis suggests that in patients with cancer and T2DM, without a prior documented history of cardiomyopathy or HF, and who received potentially cardiotoxic antineoplastic therapies, the baseline use of SGLT2is was safe and associated with a significantly reduced risk of CTRCD, HF exacerbations, all-cause mortality, all-cause hospitalizations/ED visits, new onset atrial fibrillation/flutter, new onset metastatic cancer, and the need for systemic antineoplastic therapy. More extensive prospective randomized trials are warranted to validate the role of SGLT2is as a viable primary prevention strategy for patients exposed to cancer treatment with the potential for cardiotoxicity.

FUNDING SUPPORT AND AUTHOR DISCLOSURES

Dr Yang has received research funding from CSL Behring (nonrelevant), Boehringer Ingelheim and Eli and Lilly, Amgen (nonrelevant), and Bristol Meyers Squibb (nonrelevant); and has received consulting fees from Xencor (nonrelevant). Dr Deswal has received consulting fees from Bayer. Dr Herrmann has received consulting fees from Pfizer, Astellas, and AstraZeneca; and has received grant funding from the National Institutes of Health (RO1 CA233610) and the Miami Heart Foundation. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

ADDRESS FOR CORRESPONDENCE: Dr Sarju Ganatra, Department of Medicine (Research), Cardio-Oncology Program, South Asian Cardio-Metabolic Program, Landsman Heart and Vascular Center, Lahey Hospital and Medical Center, 41 Mall Road, Burlington, Massachusetts 01805, USA. E-mail: Sarju.Ganatra@Lahey.org. X handle: [@SarjuGanatraMD](#).

PERSPECTIVES

COMPETENCY IN MEDICAL KNOWLEDGE: In our retrospective analysis, SGLT2i use at baseline was associated with a significantly decreased risk of developing CTRCD in patients with T2DM and cancer who were exposed to potentially cardiotoxic antineoplastic therapies. SGLT2is were also associated with a lower risk of

heart failure exacerbations and all-cause hospitalizations/ED visits.

TRANSLATIONAL OUTLOOK: The role of SGLT2is and other cardiometabolic modulators in the primary prevention of CTRCD needs to be further studied in a prospective clinical trial.

REFERENCES

1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*. 2015;373(22):2117-2128. <https://doi.org/10.1056/NEJMoa1504720>
2. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med*. 2019;381(21):1995-2008. <https://doi.org/10.1056/NEJMoa1911303>
3. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. *Diabetologia*. 2018;61(10):2108-2117. <https://doi.org/10.1007/s00125-018-4670-7>
4. Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. *JACC Basic Transl Sci*. 2020;5(6):632-644. <https://doi.org/10.1016/j.jacbts.2020.02.004>
5. Totzeck M, Mincu RI, Heusch G, Rassaf T. Heart failure from cancer therapy: can we prevent it? *ESC Heart Fail*. 2019;6(4):856-862. <https://doi.org/10.1002/ehf2.12493>
6. Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. *CA Cancer J Clin*. 2016;66(4):309-325. <https://doi.org/10.3322/caac.21341>
7. Zhang S, Liu X, Bawa-Khalife T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. *Nat Med*. 2012;18(11):1639-1642. <https://doi.org/10.1038/nm.2919>
8. Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. *Eur Heart J*. 2022;43(4):280-299. <https://doi.org/10.1093/eurheartj/ehab674>
9. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *Eur Heart J*. 2022;43(41):4229-4361. <https://doi.org/10.1093/eurheartj/ehac244>
10. Salloum FN, Tocchetti CG, Ameri P, et al. Priorities in cardio-oncology basic and translational science: GCOS 2023 Symposium proceedings: JACC: CardioOncology state-of-the-art review. *JACC CardioOncol*. 2023;5(6):715-731. <https://doi.org/10.1016/j.jacc.2023.08.003>
11. López-Sendón J, Álvarez-Ortega C, Zamora Añón P, et al. Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry. *Eur Heart J*. 2020;41(18):1720-1729. <https://doi.org/10.1093/eurheartj/ehaa006>
12. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. *J Am Coll Cardiol*. 2010;55(3):213-220. <https://doi.org/10.1016/j.jacc.2009.03.095>
13. Esteban-Fernández A, Carvajal Estupiñán JF, Gavira-Gómez JJ, et al. Clinical profile and prognosis of a real-world cohort of patients with moderate or severe cancer therapy-induced cardiac dysfunction. *Front Cardiovasc Med*. 2021;8:721080. <https://doi.org/10.3389/fcvm.2021.721080>
14. Shah CP, Moreb JS. Cardiotoxicity caused by targeted anticancer agents: a growing challenge. *Ther Adv Cardiovasc Dis*. 2019;13:1753944719843435. <https://doi.org/10.1177/1753944719843435>
15. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. *J Mol Cell Cardiol*. 2012;52(6):1213-1225. <https://doi.org/10.1016/j.jmcc.2012.03.006>
16. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. *Nat Rev Cancer*. 2007;7(5):332-344. <https://doi.org/10.1038/nrc2106>
17. Gongora CA, Drobni ZD, Quinaglia Araujo Costa Silva T, et al. Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines. *JACC Heart Fail*. 2022;10(8):559-567. <https://doi.org/10.1016/j.jchf.2022.03.006>
18. Abdel-Qadir H, Carrasco R, Austin PC, et al. The association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer. *JACC CardioOncol*. 2023;5(3):318-328. <https://doi.org/10.1016/j.jacc.2023.03.011>
19. Avula V, Sharma G, Kosiborod MN, et al. SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy-related cardiac dysfunction. *JACC Heart Fail*. 2024;12(1):67-78. <https://doi.org/10.1016/j.jchf.2023.08.026>
20. Dabour MS, George MY, Daniel MR, Blaes AH, Zordoky BN. The cardioprotective and anticancer effects of SGLT2 inhibitors: JACC: CardioOncology state-of-the-art review. *JACC CardioOncol*. 2024;6(2):159-182. <https://doi.org/10.1016/j.jacc.2024.01.007>
21. Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. *Circulation*. 2015;131(22):1981-1988. <https://doi.org/10.1161/CIRCULATIONAHA.114.013777>
22. Chatur S, Fu E, Vaduganathan M. Interpreting nonrandomized evidence for clinical decision making in cardio-oncology. *JACC CardioOncol*. 2023;5(3):329-331. <https://doi.org/10.1016/j.jacc.2023.05.003>
23. Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. *Ann Oncol*. 2020;31(2):171-190. <https://doi.org/10.1016/j.annonc.2019.10.023>
24. Yu AF, Lin IH, Jorgensen J, et al. Nomogram for predicting risk of cancer therapy-related cardiac dysfunction in patients with human epidermal growth factor receptor 2-positive breast cancer. *J Am Heart Assoc*. 2023;12(19):e029465. <https://doi.org/10.1161/JAHA.123.029465>
25. Fang K, Zhang Y, Liu W, He C. Effects of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: a meta-analysis of randomized controlled trials. *Heart Fail Rev*. 2021;26(1):101-109. <https://doi.org/10.1007/s10741-019-09906-x>
26. Attar A, Behnagh AK, Hosseini M, Amanollahi F, Shafiekhani P, Kabir A. Beta-

blockers for primary prevention of anthracycline-induced cardiac toxicity: an updated meta-analysis of randomized clinical trials. *Cardiovasc Ther*. 2022;2022:8367444. <https://doi.org/10.1155/2022/8367444>

27. Mir A, Badi Y, Bugazia S, et al. Efficacy and safety of cardioprotective drugs in chemotherapy-induced cardiotoxicity: an updated systematic review & network meta-analysis. *Cardiooncology*. 2023;9(1):10. <https://doi.org/10.1186/s40959-023-00159-0>

28. Ma Y, Bai F, Qin F, et al. Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials. *BMC Pharmacol Toxicol*. 2019;20:18. <https://doi.org/10.1186/s40360-019-0298-6>

29. Asnani A. Beta-blockers for primary prevention of anthracycline cardiotoxicity: not quite ready for prime time. *J Am Coll Cardiol*. 2018;71(20):2291-2292. <https://doi.org/10.1016/j.jacc.2018.03.461>

30. Lewinter C, Nielsen TH, Edfors LR, et al. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. *Eur Heart J*. 2022;43(27):2562-2569. <https://doi.org/10.1093/eurheartj/ehab843>

31. Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. *Eur Heart J*. 2016;37(21):1671-1680. <https://doi.org/10.1093/eurheartj/ehw022>

32. Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECY trial. *J Am Coll Cardiol*. 2018;71(20):2281-2290. <https://doi.org/10.1016/j.jacc.2018.02.049>

33. Maier RH, Plummer C, Kasim AS, et al. Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT). *BMJ Open*. 2022;12(12):e066252. <https://doi.org/10.1136/bmjopen-2022-066252>

34. Neilan TG, Quinaglia T, Onoue T, et al. Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial. *JAMA*. 2023;330(6):528-536. <https://doi.org/10.1001/jama.2023.11887>

35. Xie J, Weiskirchen R. What does the "AKT" stand for in the name "AKT kinase"? some historical comments. *Front Oncol*. 2020;10:1329.

36. Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis. *Circulation*. 2022;146(18):1383-1405. <https://doi.org/10.1161/CIRCULATIONAHA.122.061732>

37. Oh CM, Cho S, Jang JY, et al. Cardioprotective potential of an SGLT2 inhibitor against doxorubicin-induced heart failure. *Korean Circ J*. 2019;49(12):1183-1195. <https://doi.org/10.4070/kcj.2019.0180>

38. Quagliariele V, De Laurentis M, Rea D, et al. SGLT2 inhibitor dapagliflozin against anthracycline and trastuzumab-induced cardiotoxicity: the role of MYD88, NLRP3, leukotrienes/interleukin 6 axis and mTORC1 /FoxO1/3a mediated apoptosis. *Eur Heart J*. 2020;41(suppl 2):ehaa946.3253. <https://doi.org/10.1093/ehjci/ehaa946.3253>

39. Menichelli D, Vicario T, Ameri P, et al. Cancer and atrial fibrillation: epidemiology, mechanisms, and anticoagulation treatment. *Prog Cardiovasc Dis*. 2021;66:28-36. <https://doi.org/10.1016/j.pcad.2021.04.004>

40. Bao Y, Lee J, Thakur U, Ramkumar S, Marwick TH. Atrial fibrillation in cancer survivors – a systematic review and meta-analysis. *Cardiooncology*. 2023;9:29. <https://doi.org/10.1186/s40959-023-00180-3>

41. Kattelus H, Kesäniemi YA, Huikuri H, Ukkola O. Cancer increases the risk of atrial fibrillation during long-term follow-up (OPERA study). *PLoS One*. 2018;13(10):e0205454. <https://doi.org/10.1371/journal.pone.0205454>

42. Onoue T, Kang Y, Lefebvre B, et al. Impact of atrial fibrillation on heart failure in patients treated with anthracycline chemotherapy. *Am J Cardiol*. 2024;211:268-274. <https://doi.org/10.1016/j.amjcard.2023.11.038>

43. Fernandes GC, Fernandes A, Cardoso R, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. *Heart Rhythm*. 2021;18(7):1098-1105. <https://doi.org/10.1016/j.hrthm.2021.03.028>

44. Li HL, Lip GYH, Feng Q, et al. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. *Cardiovasc Diabetol*. 2021;20(1):100. <https://doi.org/10.1186/s12933-021-01293-8>

45. Filippatos TD, Lontos A, Papakitsou I, Elisaf MS. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. *Postgrad Med*. 2019;131(2):82-88. <https://doi.org/10.1080/00325481.2019.1581971>

46. Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Cancer therapy-related cardiac dysfunction: an overview for the clinician. *Clin Med Insights Cardiol*. 2019;13:1179546819866445. <https://doi.org/10.1177/1179546819866445>

47. Lenihan DJ, Cardinale DM. Late cardiac effects of cancer treatment. *J Clin Oncol*. 2012;30(30):3657-3664. <https://doi.org/10.1200/JCO.2012.45.2938>

48. Chiang CH, Chiang CH, Chiang CH, et al. Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer. *Heart*. 2023;109(6):470-477. <https://doi.org/10.1136/heartjnl-2022-321545>

49. Huang YM, Chen WM, Jao AT, Chen M, Shia BC, Wu SY. Effects of SGLT2 inhibitors on clinical cancer survival in patients with type 2 diabetes. *Diabetes Metab*. 2024;50(1):101500. <https://doi.org/10.1016/j.diabet.2023.101500>

50. Komatsu S, Nomiya T, Numata T, et al. SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation. *Endocr J*. 2020;67(1):99-106. <https://doi.org/10.1507/endocrj.EJ19-0428>

51. Scafoglio C, Hirayama BA, Kepe V, et al. Functional expression of sodium-glucose transporters in cancer. *Proc Natl Acad Sci U S A*. 2015;112(30):E4111-E4119. <https://doi.org/10.1073/pnas.1511698112>

52. Scafoglio CR, Villegas B, Abdelhady G, et al. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. *Sci Transl Med*. 2018;10(467):eaat5933. <https://doi.org/10.1126/scitranslmed.aat5933>

53. Villani LA, Smith BK, Marcinko K, et al. The diabetes medication canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. *Mol Metab*. 2016;5(10):1048-1056. <https://doi.org/10.1016/j.molmet.2016.08.014>

54. Lawler T, Walts ZL, Steinwandel M, et al. Type 2 diabetes and colorectal cancer risk. *JAMA Netw Open*. 2023;6(11):e2343333. <https://doi.org/10.1001/jamanetworkopen.2023.43333>

55. Modzelewski KL, Pipilas A, Bosch NA. Comparative outcomes of empagliflozin to dapagliflozin in patients with heart failure. *JAMA*. 2024;7(5):e249305. <https://doi.org/10.1001/jamanetworkopen.2024.9305>

56. Riaz M, Smith SM, Dietrich EA, Winchester DE, Guo J, Park H. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction. *Pharmacotherapy*. 2023;43(10):1024-1031. <https://doi.org/10.1002/phar.2853>

57. Khadke S, Kumar A, Al-Kindi S, et al. Association of environmental injustice and cardiovascular diseases and risk factors in the United States. *J Am Heart Assoc*. 2024;13(7):e033428. <https://doi.org/10.1161/JAHA.123.033428>

KEY WORDS antineoplastic therapy, cardiomyopathy, CTRCD, primary prevention, sodium glucose co-transporter 2 inhibitors

APPENDIX For supplemental appendix, please see the online version of this paper.